4 completed, 2 active not recruiting, 2 recruiting, 1 terminated. 6 Phase 3, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 2, Recruiting 2, Completed 1, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow ziltivekimab: new trials by email Literature Review of ziltivekimab trials Research Report on ziltivekimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction Ziltivekimab, Placebo - Coronary Artery Disease, Acute Myocardial Infarction (AMI) | Phase 3 | Recruiting | ECRI bv | 332 | 2025-12-19 | 2026-03-23 |
| A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack Ziltivekimab, Ziltivekimab Placebo - Myocardial Infarction | Phase 3 | Recruiting | Novo Nordisk A/S | 332 | 2025-12-18 | 2026-03-11 |
| ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack Ziltivekimab, Placebo - Cardiovascular Risk, Acute Myocardial Infarction (AMI) | Phase 3 | Active not recruiting | Novo Nordisk A/S | 10000 | 2024-06-25 | 2026-09-09 |
| Specifying the Anti-inflammatory Effects of Ziltivekimab Ziltivekimab, Placebo - Atherosclerosis, Inflammation | Phase 3 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 40 | 2024-05-03 | 2026-11-06 |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation Ziltivekimab, Placebo - Heart Failure, Systemic Inflammation | Phase 3 | Active not recruiting | Novo Nordisk A/S | 673 | 2024-04-01 | 2026-10-01 |
| A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation Ziltivekimab, Placebo - Heart Failure | Phase 3 | Terminated | Novo Nordisk A/S | 4874 | 2023-05-08 | 2026-10-01 |
| A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation Ziltivekimab, Placebo - Chronic Kidney Disease and Systemic Inflammation | Phase 1 | Completed | Novo Nordisk A/S | 24 | 2022-05-30 | 2025-12-31 |
| Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan. Ziltivekimab, Placebo (ziltivekimab) - Chronic Kidney Disease, Inflammation | Phase 2 | Completed | Novo Nordisk A/S | 36 | 2020-10-22 | 2026-05-06 |
| Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition Ziltivekimab - Chronic Kidney Diseases, Inflammation | Phase 2 | Completed | Novo Nordisk A/S | 264 | 2019-06-03 | 2025-12-31 |
Inflammation (3) · Renal Insufficiency, Chronic (3) · Atherosclerosis (2) · Heart Failure (2) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Myocardial Infarction (1)
Novo Nordisk A/S (7) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · ECRI bv (1)
Netherlands (4) · Spain (4) · United States (4) · Argentina (3) · Australia (3) · Bulgaria (3) · Canada (3) · China (3) · Czechia (3) · Denmark (3) · France (3) · Germany (3) · Greece (3) · India (3) · Italy (3)
PMID 34015342, PMID 35212585, PMID 37211246, PMID 38088558, PMID 39073758, PMID 41805697
2023 (2)